(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The next-generation β-particle–emitting radioimmunoconjugate (177)Lu-lilotomab-satetraxetan (Betalutin) was shown to up-regulate CD20 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539655/
https://www.ncbi.nlm.nih.gov/pubmed/32245896
http://dx.doi.org/10.2967/jnumed.119.237230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539655/
https://www.ncbi.nlm.nih.gov/pubmed/32245896
http://dx.doi.org/10.2967/jnumed.119.237230

Ejemplares similares